2021 American Transplant Congress
Impact of a Cmv Cell Mediated Immunity Based Protocol on Guiding Cmv Prophylaxis Following Pediatric Liver Transplantation – A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is an important cause of morbidity following pediatric orthotopic liver transplantation (OLT), especially among high risk (HR) CMV D+/R- recipients. In 2019,…2021 American Transplant Congress
Discontinuation of Trimethoprim/sulfamethoxazole Prophylaxis Due to Hyperkalemia in Kidney Transplant Recipients
*Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in kidney transplant recipients (KTRs), however, it can be complicated by…2021 American Transplant Congress
Evaluating Pneumocystis Jiroveci Pneumonia Prophylaxis in Lung Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: The incidence of Pneumocystis jiroveci pneumonia (PJP) in lung transplant recipients (LTRs) on PJP prophylaxis is not well documented yet reported as high as…2021 American Transplant Congress
An Unusual Viral Tropism in a Solid Organ Transplant Recipient
*Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…2021 American Transplant Congress
De Novo Hepatitis B Infection Following Liver Transplant with Hepatitis B Core Antibody Positive Graft
*Purpose: The risk of de novo HBV infection in liver transplant recipients of Hepatitis B core antibody (HBcAb) positive donor organs is tempered by availability…2021 American Transplant Congress
Incidence of Oral Candidiasis in Renal and/or Pancreas Transplant Recipients When Administering Prophylaxis versus No Prophylaxis
*Purpose: Oropharyngeal candidiasis (OC), or thrush, is a fungal infection associated with immunosuppression post renal and or/pancreas transplant. Currently, the role of prophylactic oral nystatin…2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2020 American Transplant Congress
Stewardship Effortsto Eliminate Post-Orthotopic Liver Transplant Antibiotics in Uncomplicated Patients Leads to Equivalent Safety Outcomes
University of Virginia Health System, Charlottesville, VA
*Purpose: The purpose of this study was to evaluate safety and efficacy endpoints of a revised post-operative antibiotic prophylaxis protocol in orthotopic liver transplant (OLT)…2020 American Transplant Congress
Pneumocystis Pneumonia Occurrence and Prophylaxis Duration in Kidney Transplant Recipients According to Perioperative Treatment with Rituximab
Department of Surgery, Division of Kidney and Pancreas Transplant, AMC, Seoul, Korea, Republic of
*Purpose: Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving…2020 American Transplant Congress
Role of Tacrolimus Dose Adjustment at Discontinuation of Fluconazole in Liver Transplant
University of Virginia Health System, Charlottesville, VA
*Purpose: The purpose of this study was to characterize the effects of fluconazole (fluc) discontinuation on tacrolimus (tac) levels and the role of prophylactic dose…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 14
- Next Page »